RT Journal Article
SR Electronic
T1 Human ASXL1 Deficiency Causes Epigenetic Dysfunction, Combined Immunodeficiency and EBV–Associated Hodgkin Lymphoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.20.23300096
DO 10.1101/2023.12.20.23300096
A1 Fu, Maggie P
A1 Sharma, Mehul
A1 Merrill, Sarah M
A1 Yousefi, Pariya
A1 Tan, Ryan
A1 Modi, Bhavi P
A1 Bel, Kate Del
A1 Deyell, Rebecca J
A1 Rozmus, Jacob
A1 Rehmus, Wingfield
A1 Hildebrand, Kyla J
A1 James, Elliot
A1 Blanchard-Rohner, Géraldine
A1 Lin, Susan
A1 Shopsowitz, Kevin E
A1 Setiadi, Audi
A1 Terry, Jefferson
A1 Lee, Anna F
A1 Drögemöller, Britt I
A1 Matthews, Allison
A1 Tarailo-Graovac, Maja
A1 Sauvé, Laura
A1 Mitchell, Hana
A1 Prendiville, Julie S
A1 MacIsaac, Julie L
A1 Dever, Kristy
A1 Lin, David T S
A1 Meijer, Mandy
A1 Ross, Colin J D
A1 Dobson, Simon R M
A1 Vercauteren, Suzanne M
A1 Wasserman, Wyeth W
A1 van Karnebeek, Clara D M
A1 McKinnon, Margaret L
A1 Kobor, Michael S
A1 Turvey, Stuart E
A1 Biggs, Catherine M
YR 2023
UL http://medrxiv.org/content/early/2023/12/21/2023.12.20.23300096.abstract
AB Inborn errors of immunity (IEI) are a group of disorders caused by deleterious variants in immune-related genes, including some that function as epigenetic regulators. Additional sex combs-like 1 (ASXL1) is an epigenetic modifier that has not previously been linked to an IEI. Somatic ASXL1 variants are found in clonal hematopoiesis and hematologic neoplasms, while heterozygous germline variants cause Bohring–Opitz syndrome. We present a new IEI caused by biallelic germline variants in ASXL1. The patient had a complex and unusual history of disease progression notable for persistent cutaneous vaccine-strain rubella granulomas initially manifesting in early childhood, chronic macrocytosis and mild bone marrow cellular hypoplasia, and Epstein Barr virus– associated Hodgkin lymphoma in adolescence. Detailed immunophenotyping revealed progressive loss of B-cells, hypogammaglobinemia, and T-cell lymphopenia with severe skewing toward a memory phenotype and elevated expression of T-cell exhaustion and senescence markers. Molecular investigations confirmed ASXL1 protein deficiency in the patient’s T-cells and fibroblasts. The T-cells exhibited marked loss of DNA methylation, increased epigenetic aging, and CD8 T-cell dysfunction. These aberrations were ameliorated by lentivirus-mediated transduction with wild-type ASXL1, confirming the pathogenicity of ASXL1 variants. This study defines a novel human IEI caused by ASXL1 deficiency, a diagnosis that should be considered in individuals with chronic viral infections, virus-associated hematologic malignancies, and combined immunodeficiency. Furthermore, our findings provide fresh insights into the mechanisms underlying the roles of human ASXL1 in T-cell function as well as in the development and maintenance of lymphomas.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Canadian Institutes of Health Research (EGM-141897) (M.S.K.) (PJT-178054) (S.E.T., C.M.B.), Genome British Columbia (SIP007) (S.E.T.), Michael Smith Health Research BC (HPI-2018-2014) (C.M.B.) and BC Children's Hospital Foundation. M.S.K. is the Edwin S.H. Leong UBC Chair in Healthy Aging, C.M.B. is a MSHRBC Health Professional-Investigator, and S.E.T. holds a Tier 1 Canada Research Chair in Pediatric Precision Health and the Aubrey J. Tingle Professor of Pediatric Immunology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Clinical Research Ethics Board of the University of British Columbia gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data produced in the present study is available upon reasonable request to the corresponding author.